March 4, 2024

Cidara Therapeutics Moving on FDA Advisory Committee Recommendation

(24/7 MARKET NEWS) – Cidara Therapeutics, Inc. (Nasdaq:CDTX) and Melinta Therapeutics, LLC reported, this morning, that the FDA Antimicrobial Drugs Advisory Committee voted favorably 14 to 1 that Cidara, as part of its New Drug Application (NDA), provided sufficient evidence supporting a favorable benefit-risk assessment for a limited use indication for rezafungin for the treatment of candidemia and invasive candidiasis in adult patients with limited or no alternative treatment options.

Cidara Therapeutics opened this morning’s trading at $1.07 and is now at $0.9616, up $0.0335 (+3.61%), on volume of 10 million shares traded.

Its 52-week range is $0.40 to $1.60. Its next key inflection points are $1.41, $1.53, and this morning’s premarket high of $1.68. If can break through the $1.68 resistance level, on strong volume, it could try to challenge its February trading levels.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.